Literature DB >> 1556903

Ibogaine antagonizes cocaine-induced locomotor stimulation in mice.

H Sershen1, A Hashim, L Harsing, A Lajtha.   

Abstract

Ibogaine (40 mg/kg i.p.), when given 2 hours before an acute injection of cocaine (25 mg/kg s.c.) to C57BL/6 mice, reduced the cocaine-induced locomotor stimulation. Such stimulation was also reduced in the ibogaine-treated mice when a second injection of cocaine was given 24 hr later. Thus, the reduction in locomotor activity was not just the short-term depression of locomotor activity seen after ibogaine administration. When mice were given a daily injection of cocaine for 3 days and ibogaine was given after the cocaine injection on day 3, and again on day 4, cocaine-induced locomotor activity was reduced three hours later on day 4. On days 5 and 9 of the cocaine administration, with no further ibogaine treatment ambulatory counts were still lower in the ibogaine-pretreated mice. Locomotor stimulation induced by amphetamine (10 mg/kg) was not affected by ibogaine. An acute injection of ibogaine resulted in a transient increase in turnover of dopamine, as indicated by the increase in the ratio of metabolites of the dopamine to dopamine, followed by a decrease in the metabolites in striatum and frontal cortex 24 hr later. In vivo treatment with ibogaine did not affect the binding of [3H]WIN 35,248 to the cocaine binding site in striatal tissue measured in vitro. In addition, ibogaine added in vitro had a weak affinity to the WIN 35,248 binding site (IC50 for cocaine = 120 nM and for ibogaine = 1,500 nM). The results suggest that ibogaine may have induced a selective change in the dopaminergic system that results in a decrease in responsiveness to cocaine that persisted for at least 1 week.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1556903     DOI: 10.1016/0024-3205(92)90344-o

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

Review 1.  Kappa opioids as potential treatments for stimulant dependence.

Authors:  Thomas E Prisinzano; Kevin Tidgewell; Wayne W Harding
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

2.  Neuropharmacological characterization of local ibogaine effects on dopamine release.

Authors:  M S Reid; K Hsu; K H Souza; P A Broderick; S P Berger
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Medical marijuana users in substance abuse treatment.

Authors:  Ronald Swartz
Journal:  Harm Reduct J       Date:  2010-03-05

4.  Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine.

Authors:  J K Staley; Q Ouyang; J Pablo; W L Hearn; D D Flynn; R B Rothman; K C Rice; D C Mash
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

5.  Effect of ibogaine on serotonergic and dopaminergic interactions in striatum from mice and rats.

Authors:  H Sershen; A Hashim; A Lajtha
Journal:  Neurochem Res       Date:  1994-11       Impact factor: 3.996

6.  Evidence that ibogaine releases dopamine from the cytoplasmic pool in isolated mouse striatum.

Authors:  L G Harsing; H Sershen; A Lajtha
Journal:  J Neural Transm Gen Sect       Date:  1994

7.  The putative anti-addictive drug ibogaine is a competitive inhibitor of [3H]MK-801 binding to the NMDA receptor complex.

Authors:  P Popik; R T Layer; P Skolnick
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

8.  Effects of ibogaine on responding maintained by food, cocaine and heroin reinforcement in rats.

Authors:  S I Dworkin; S Gleeson; D Meloni; T R Koves; T J Martin
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

9.  Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity.

Authors:  P M Sweetnam; J Lancaster; A Snowman; J L Collins; S Perschke; C Bauer; J Ferkany
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

10.  Prior morphine exposure enhances ibogaine antagonism of morphine-induced locomotor stimulation.

Authors:  S M Pearl; D W Johnson; S D Glick
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.